SEARCH:   Advanced

Blood, 15 November 2004, Vol. 104, No. 10, pp. 3009-3020. Prepublished online as a Blood First Edition Paper on July 20, 2004; DOI 10.1182/blood-2004-02-0405. This Article Full Text (PDF) All Versions of this Article: 2004-02-0405v1 104/10/3009    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Blum, K. A Articles by Byrd, J. C Search for Related Content PubMed PubMed Citation Articles by Blum, K. A Articles by Byrd, J. C Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted February 5, 2004 Accepted May 8, 2004 Adult Burkitt's Leukemia and Lymphoma Kristie A Blum*, Gerard Lozanski, and John C Byrd Division of Hematology and Oncology, Ohio State University, Columbus, Ohio, USA Division of Pathology, The Ohio State University, Columbus, Ohio, USA Division of Hematology and Oncology, Ohio State University, Columbus, Ohio, USA; Division of Medicinal Chemistry, Department of Pharmacy, Ohio State University, Columbus, Ohio, USA * Corresponding author; email: blum-2{at}medctr.osu.edu. The World Health Organization classification of lymphoid neoplasms identifies Burkitt lymphoma/leukemia as a highly aggressive mature B-cell neoplasm consisting of sporadic, endemic, and immunodeficiency-associated variants. These subtypes share many morphologic and immunophenotypic features, but differences exist in their clinical and geographic presentations. All of these subtypes possess chromosomal rearrangements of the c-myc oncogene, the genetic hallmark of Burkitt lymphoma, that contributes to lymphomagenesis through alterations in cell cycle regulation, cellular differentiation, apoptosis, cellular adhesion, and metabolism. Brief duration, high intensity chemotherapy regimens containing aggressive central nervous system prophylaxis have had remarkable success in the treatment of this disease, with complete remission rates of 75-90% and overall survivals reaching 50-70% in adults. Although Burkitt lymphoma cells are extremely chemosensitive, biologically targeted therapies should be developed as current treatment options are suboptimal for patients with poor prognostic features or in the setting of relapsed disease. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. Villa, J. M. Connors, T. N. Shenkier, R. D. Gascoyne, L. H. Sehn, and K. J. Savage Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy Ann. Onc., October 27, 2009; (2009) mdp432v1. [Abstract] [Full Text] [PDF] D. de Jong Novel lymphoid neoplasms - the borderland between diffuse large B-cell lymphoma and Burkitt's lymphoma Haematologica, July 1, 2009; 94(7): 894 - 896. [Full Text] [PDF] S. Sander, L. Bullinger, K. Klapproth, K. Fiedler, H. A. Kestler, T. F. E. Barth, P. Moller, S. Stilgenbauer, J. R. Pollack, and T. Wirth MYC stimulates EZH2 expression by repression of its negative regulator miR-26a Blood, November 15, 2008; 112(10): 4202 - 4212. [Abstract] [Full Text] [PDF] G. M. Mead, S. L. Barrans, W. Qian, J. Walewski, J. A. Radford, M. Wolf, S. M. Clawson, S. P. Stenning, C. L. Yule, A. S. Jack, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial) Blood, September 15, 2008; 112(6): 2248 - 2260. [Abstract] [Full Text] [PDF] G Brady, G J MacArthur, and P J Farrell Epstein-Barr virus and Burkitt lymphoma Postgrad. Med. J., July 1, 2008; 84(993): 372 - 377. [Abstract] [Full Text] [PDF] S. Quijano, A. Lopez, A. Rasillo, S. Barrena, M. Luz Sanchez, J. Flores, C. Fernandez, J. M. Sayagues, C. S. Osuna, N. Fernandez, et al. Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients Blood, May 15, 2008; 111(10): 5130 - 5141. [Abstract] [Full Text] [PDF] P. R. Bhosale, M. Patnana, C. Viswanathan, and J. Szklaruk The Inguinal Canal: Anatomy and Imaging Features of Common and Uncommon Masses RadioGraphics, May 1, 2008; 28(3): 819 - 835. [Abstract] [Full Text] [PDF] G Brady, G J MacArthur, and P J Farrell Epstein Barr virus and Burkitt lymphoma J. Clin. Pathol., December 1, 2007; 60(12): 1397 - 1402. [Abstract] [Full Text] [PDF] V. Truffinet, E. Pinaud, N. Cogne, B. Petit, L. Guglielmi, M. Cogne, and Y. Denizot The 3' IgH Locus Control Region Is Sufficient to Deregulate a c-myc Transgene and Promote Mature B Cell Malignancies with a Predominant Burkitt-Like Phenotype J. Immunol., November 1, 2007; 179(9): 6033 - 6042. [Abstract] [Full Text] [PDF] L. Galicier, C. Fieschi, R. Borie, V. Meignin, M.-T. Daniel, L. Gerard, and E. Oksenhendler Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study Blood, October 15, 2007; 110(8): 2846 - 2854. [Abstract] [Full Text] [PDF] P. Lin and L. J. Medeiros High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis Haematologica, October 1, 2007; 92(10): 1297 - 1301. [Full Text] [PDF] J. A. Mertz, R. Kobayashi, and J. P. Dudley ALY Is a Common Coactivator of RUNX1 and c-Myb on the Type B Leukemogenic Virus Enhancer J. Virol., April 1, 2007; 81(7): 3503 - 3513. [Abstract] [Full Text] [PDF] M. S. Lam Treatment of Burkitt's Lymphoma During Pregnancy Ann. Pharmacother., November 1, 2006; 40(11): 2048 - 2052. [Abstract] [Full Text] [PDF] A. Liso, D. Capello, T. Marafioti, E. Tiacci, M. Cerri, V. Distler, M. Paulli, A. Carbone, G. Delsol, E. Campo, et al. Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma Blood, August 1, 2006; 108(3): 1013 - 1020. [Abstract] [Full Text] [PDF] D. P. Smith, M. L. Bath, D. Metcalf, A. W. Harris, and S. Cory MYC levels govern hematopoietic tumor type and latency in transgenic mice Blood, July 15, 2006; 108(2): 653 - 661. [Abstract] [Full Text] [PDF] J. A. Ferry Burkitt's Lymphoma: Clinicopathologic Features and Differential Diagnosis. Oncologist, April 1, 2006; 11(4): 375 - 383. [Abstract] [Full Text] [PDF] N. Syed, P. Smith, A. Sullivan, L. C. Spender, M. Dyer, L. Karran, J. O'Nions, M. Allday, I. Hoffmann, D. Crawford, et al. Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies Blood, January 1, 2006; 107(1): 250 - 256. [Abstract] [Full Text] [PDF] E. J. Jabbour, S. Faderl, and H. M. Kantarjian Adult Acute Lymphoblastic Leukemia Mayo Clin. Proc., November 1, 2005; 80(11): 1517 - 1527. [Abstract] [PDF] S. T. Lim, R. Karim, B. N. Nathwani, A. Tulpule, B. Espina, and A. M. Levine AIDS-Related Burkitt's Lymphoma Versus Diffuse Large-Cell Lymphoma in the Pre-Highly Active Antiretroviral Therapy (HAART) and HAART Eras: Significant Differences in Survival With Standard Chemotherapy J. Clin. Oncol., July 1, 2005; 23(19): 4430 - 4438. [Abstract] [Full Text] [PDF] Y. Sun, S. Orrenius, S. Pervaiz, and B. Fadeel Plasma membrane sequestration of apoptotic protease-activating factor-1 in human B-lymphoma cells: a novel mechanism of chemoresistance Blood, May 15, 2005; 105(10): 4070 - 4077. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020